Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia
- PMID: 19486273
- DOI: 10.1111/j.1600-079X.2009.00681.x
Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia
Abstract
We conducted this study to assess long-term melatonin treatment course, effectiveness and safety in children with attention-deficit/hyperactivity disorder (ADHD) and chronic sleep onset insomnia (CSOI). This was conducted by means of a structured questionnaire for the parents. The subjects of this study consisted of participants who previously participated in a randomised clinical trial on melatonin efficacy. The response rate was 93% (94/101). The mean time to follow up was 3.7 yr. No serious adverse events or treatment related co-morbidities were reported. Sixty-five percent of the children still used melatonin daily and 12% occasionally. Temporal discontinuation of treatment resulted in a delay of sleep onset in 92% of the children. Nine percent of the children could discontinue melatonin completely because of improvement of sleep onset insomnia. Long-term melatonin treatment was judged to be effective against sleep onset problems in 88% of the cases. Improvement of behaviour and mood was reported in 71% and 61% respectively. We conclude that melatonin remains an effective therapy on the long term for the treatment of CSOI in children with ADHD and has no safety concerns regarding serious adverse events or treatment related co-morbidity. Discontinuation of melatonin treatment usually leads to a relapse of sleep onset insomnia and in resuming melatonin treatment, even after several years of treatment.
Similar articles
-
[Disturbed sleep in children with ADHD: is there a place for melatonin as a treatment option?].Tijdschr Psychiatr. 2013;55(5):349-57. Tijdschr Psychiatr. 2013. PMID: 23696337 Review. Dutch.
-
Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder.Ann Pharmacother. 2010 Jan;44(1):185-91. doi: 10.1345/aph.1M365. Epub 2009 Dec 22. Ann Pharmacother. 2010. PMID: 20028959 Review.
-
Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.J Intellect Disabil Res. 2008 Mar;52(Pt 3):256-64. doi: 10.1111/j.1365-2788.2007.01016.x. J Intellect Disabil Res. 2008. PMID: 18261024 Clinical Trial.
-
Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders.J Pineal Res. 2007 Nov;43(4):351-9. doi: 10.1111/j.1600-079X.2007.00485.x. J Pineal Res. 2007. PMID: 17910603 Clinical Trial.
-
Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia.J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):233-41. doi: 10.1097/01.chi.0000246055.76167.0d. J Am Acad Child Adolesc Psychiatry. 2007. PMID: 17242627 Clinical Trial.
Cited by
-
Adherence to treatment and parents' perspective about effectiveness of melatonin in children with autism spectrum disorder and sleep disturbances.Child Adolesc Psychiatry Ment Health. 2023 Oct 27;17(1):123. doi: 10.1186/s13034-023-00669-w. Child Adolesc Psychiatry Ment Health. 2023. PMID: 37891596 Free PMC article.
-
The impact of sleep difficulties in children with attention deficit hyperactivity disorder on the family: a thematic analysis.J Clin Sleep Med. 2023 Oct 1;19(10):1735-1741. doi: 10.5664/jcsm.10662. J Clin Sleep Med. 2023. PMID: 37786381
-
The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessment.EClinicalMedicine. 2023 Jul 6;61:102083. doi: 10.1016/j.eclinm.2023.102083. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37483551 Free PMC article.
-
Delayed sleep-wake phase disorder and its related sleep behaviors in the young generation.Front Psychiatry. 2023 May 19;14:1174719. doi: 10.3389/fpsyt.2023.1174719. eCollection 2023. Front Psychiatry. 2023. PMID: 37275982 Free PMC article. Review.
-
Chronic Administration of Melatonin: Physiological and Clinical Considerations.Neurol Int. 2023 Mar 15;15(1):518-533. doi: 10.3390/neurolint15010031. Neurol Int. 2023. PMID: 36976674 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical